I really don't want to be a doctor

Chapter 436
The "Atrial Fibrillation" forum started with sparse applause from the crowd.

Jing Xiaoran sat in the first row, as the third speaker, waiting to give a speech.

The two speakers before him were cardiologists from the top tertiary hospitals in China.

The first doctor to give a speech had an old-fashioned style. He was wearing a black suit and thick black glasses. At first glance, he looked like the head of the department who had been in a high position for many years.

Jing Xiaoran glanced at his introduction, the deputy director of the Cardiology Department of West China Hospital.

This title is quite big, the most top hospital in China, even a deputy chief physician, has experienced many battles and has countless SCI papers.

After the introduction, his presentation began.

"Atrial fibrillation is the most common sustained cardiac arrhythmia. The incidence of atrial fibrillation increases with age, reaching up to 75% of people over the age of 10."

"Atrial fibrillation has a frequency of 300-600 beats per minute, and the heartbeat frequency is often fast and irregular, sometimes up to 100-160 beats per minute, which is not only much faster than normal heartbeats, but also absolutely irregular. Loss of effective systolic function. The prevalence of atrial fibrillation is also closely related to diseases such as coronary heart disease, hypertension and heart failure."

……

The deputy chief physician's speech was quite satisfactory. Although there were some latest research contents, he didn't get to the point.

It seems that this PPT was not made by himself.

If Jing Xiaoran hadn't known this cutting-edge knowledge in advance, he would definitely have been confused.

After 10 minutes, the old doctor's speech ended.

There were still only about 20 people in the conference hall, and a few people even left.

"The second speaker is a representative of our new generation of young doctors, Feng Xi, the attending physician of the Department of Cardiology at Sun Yat-Sen Medical College." Zhou Jingbo introduced.

Jing Xiaoran glanced at the resume of the second speaker.

This is really a golden piece. I studied in the copy department of the top medical students in China, and then studied for a master's degree at Harvard Medical School. During my study, I published three top-level papers
In the end, he received many invitations from the principal of Sun Yat-Sen Medical College, and he was willing to return to China.

The key point is that he is still young and less than 30 years old, and the future is absolutely limitless!

Feng Xi came to the stage with a gentle smile on his face.

"The topic of my speech this time is the application of warfarin in atrial fibrillation."

"Warfarin is a kind of coumarin anticoagulant, which has an anti-vitamin K effect in the body. It can inhibit the synthesis of blood coagulation factors II, VII, IX, and X involved in vitamin K in the liver. Some coagulation factors Ⅱ, Ⅶ, Ⅸ, Ⅹ have no resistance. Anticoagulation in the body can only be effective after the consumption of active coagulation factors, and the effect and maintenance time after the onset of effect are also longer. It is mainly used to prevent and treat thromboembolic diseases ..."

Compared with the first old doctor, Feng Xi's speech was richer in content, and he is worthy of being a returnee who returned from studying in the United States, and the PPT was quite exquisitely produced.

Jing Xiaoran was also attentively listening to Feng Xi's speech.

Unknowingly, in the conference hall, dozens of attendees came, and there seemed to be an increasing trend.

By the end of Feng Xi's speech, half of the seats in the conference hall were full.

"The next thing is our third and last speaker this morning. He is Jing Xiaoran from Shenzhou Biological Medicine Laboratory."

It was Jing Xiaoran's turn.

He cleared his throat, stood up slowly, and walked to the stage.

The audience are all doctors from all corners of the country.

It was also the first time for Jing Xiaoran to speak on such an occasion.

"Jing Xiaoran is the head of the Shenzhou Laboratory. He developed a new type of oral anticoagulant drug when he was in college. This drug has changed the ecology of anticoagulant drugs and brought good news to countless patients..."

The host Zhou Jingbo began to introduce Jing Xiaoran's background and identity. At the same time, as an expert in cardiology, he knew very well about this new type of oral anticoagulant drug.

Zhou Jingbo has been using this drug since it was launched, and he is one of the first batch of doctors to use new oral anticoagulant drugs.

"The research and development of new oral anticoagulant drugs is definitely one of the most successful drugs in medical history. The most important thing is that its developer is our countryman, and he is also Jing Xiaoran standing in front of everyone."

Zhou Jingbo's introduction to Jing Xiaoran was very detailed, and it took twice as long as the previous introduction!
The audience here was a little impatient at the beginning. Listening to textbooks is a very boring thing, and it is too early to waste time on identity introduction.

But when everyone heard that Jing Xiaoran was the developer of the "new oral anticoagulant drug", everyone was surprised!
Most people know about this drug, after all, it has been on the market for a while.

However, except for a very small number of people, everyone does not know who developed this drug. They only know that it was produced by Pfizer, so they naturally think that it was also produced by Pfizer's internal R&D team.

In fact, buying and selling drug patents is very common, which also leads to the fact that the real drug developers are often unknown.

Moreover, the research and development of drugs often requires the efforts of the entire team, which cannot be completed by one or two people, so everyone naturally ignores the existence of drug developers.

"Did the Huaxia people develop new oral anticoagulant drugs?"

There was a question in the hearts of most people in the audience.

From the beginning of clinical trials of new oral anticoagulant drugs to the current research and development, Pfizer has given a lot of publicity resources.

Almost all large hospitals in China, and even in the whole of China, have medical representatives of new oral anticoagulant drugs.

"Who is this person?"

Some older doctors whispered to those around them.

"The person in charge of the Shenzhou Laboratory."

"What is this Shenzhou laboratory? Which university's affiliated laboratory?"

"A private laboratory."

"Private? When did Huaxia produce such a powerful laboratory?"

There was a lot of discussion in the audience, people kept asking who is "Jing Xiaoran".

Jing Xiaoran couldn't hear the discussion in the audience, he just felt that the audience suddenly became a little noisy?
As the youngest speaker in the audience, don't everyone treat him with such disrespect?

But I can't control it now, Jing Xiaoran started his own performance.

"New oral anticoagulants (NOACs) do not act on multiple coagulation factors like warfarin and other traditional anticoagulants, but only inhibit a certain coagulation factor. The two most important targets in the coagulation cascade are respectively Xa and IIa."

"The current new oral anticoagulant drugs specifically refer to the newly developed and marketed oral factor Xa and direct inhibitors of IIa. The former includes apixaban, rivaroxaban, edoxaban, etc., and the latter includes dabigatran."

(End of this chapter)